<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444000</url>
  </required_header>
  <id_info>
    <org_study_id>P130097</org_study_id>
    <nct_id>NCT02444000</nct_id>
  </id_info>
  <brief_title>gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas</brief_title>
  <acronym>POLCA</acronym>
  <official_title>A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association de Neuro-Oncologues d’Expression Francaise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with 1p/19q-codeleted anaplastic gliomas treated with RT + PCV are at risk of
      neurocognitive deterioration. Treating these patients with PCV alone (could reduce the risk
      of neurocognitive deterioration without impairing overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentric, Randomized phase III study (1:1), Population: newly diagnosed 1p/19-codeleted
      anaplastic gliomas, Primary objective: To determine whether treating newly diagnosed
      1p/19q-codeleted anaplastic gliomas with PCV alone can increase overall survival without
      neurocognitive deterioration Control group: radiotherapy followed by 6 cycles of PCV
      chemotherapy. Experimental group: 6 cycles of PCV chemotherapy (radiotherapy being deferred
      at the time of progression).

      Number of centres participating: the 31 centers of the POLA network Recruitment duration: 7
      years, the accrual rate being 40 patients per year, and patients are followed-up until the
      end of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without neurocognitive deterioration</measure>
    <time_frame>9 years</time_frame>
    <description>Survival without neurocognitive deterioration (whatever the cause of deterioration, i.e toxicity or tumor progression) defined as the time from study registration to failure in any of the 6 cognitive domains that will be explored (i.e memory, working memory, language, visuo-spatial ability, cognitive executive functions, behavioral executive functions) or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Anaplastic Gliomas With 1p/19q Codeletion</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCV chemotherapy alone</intervention_name>
    <description>PCV cycles are 6 weeks long
PCV chemotherapy is given as:
Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiotherapy+PCV chemotherapy</intervention_name>
    <description>Radiotherapy followed by 6 cycles of PCV</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

        Histological confirmation of anaplastic glioma by central pathological review

          -  Tumor is co-deleted for 1p and 19q

          -  Age ≥ 18 years of age

          -  Newly diagnosed and ≤3 months from surgical diagnosis

          -  Willing and able to complete neurocognitive examination and the QOL

          -  Karnofsky performance status ≥ 60

          -  The following laboratory values obtained ≤ 21 days prior to registration:

          -  Absolute neutrophil count (ANC) ≥1500 /mm3

          -  Platelet count ≥100,000 / mm3

          -  Hemoglobin &gt; 9.0 g/dL

          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

          -  SGOT (AST) ≤ 3 x ULN

          -  Negative serum or urine pregnancy test done ≤ 7 days prior to registration, for women
             of childbearing potential only.

          -  Provide informed written consent

        Exclusion criteria :

          -  Pregnant and nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception during this study and for up to 6 months following the completion of
             PCV.

          -  Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves Delattre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Yves Delattre, MD, PhD</last_name>
    <phone>+33(0) 1 42 16 03 85</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Delattre, MD, PhD</last_name>
      <phone>+33(0) 1 42 16 03 85</phone>
      <email>jean-yves.delattre@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>PCV</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>post operative treatment</keyword>
  <keyword>anaplastic gliomas</keyword>
  <keyword>1p/19q codeletion</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

